SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avalanche is a high throughput smart contract blockchain platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche (AVAX) is trending amid discussions of significant institutional interest, fueled by its potential for Real World Asset (RWA) tokenization and a new ETF filing that includes staking. Despite some investor frustration over recent price action, the community remains highly engaged, emphasizing AVAX's strong fundamentals, unique subnet architecture, and deflationary tokenomics as key drivers for future growth and adoption. The ongoing debate revolves around the disconnect between these bullish developments and current market performance.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is experiencing renewed excitement driven by broader altcoin season narratives, with the community rallying around the potential for a "zero drop". Despite recent volatility, many holders are accumulating, viewing current price action as a buying opportunity for the popular meme coin.

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

BONK is trending amid significant catalysts aimed at boosting its legitimacy and reducing supply, notably the upcoming 1 trillion token burn as the community nears 1 million holders. The recent launch of its first ETP on the SIX Swiss Exchange and new utility like the "kill-to-earn" Bonk Arena are fueling community discussions of a potential major rebound and an "alt/meme season" within the Solana ecosystem.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

SHIB is currently trending amid highly polarized community sentiment, with many debating if it's a "bull trap" or a prime "buy the dip" opportunity at perceived low prices. Discussions are rife with calls for a significant "squeeze" and the broader "alt season" narrative, even as others express skepticism and label it a "scam" or a "dead coin." The community remains deeply divided on its immediate future, reflecting ongoing volatility and uncertainty in the meme coin space.

Memecoin on Injective taken over by the community.

Nonja

NONJA CRYPTO is trending as its community actively positions it as a high-leverage play on the Injective ecosystem, anticipating significant upside with Injective's robust fundamentals and upcoming market catalysts. Enthusiasts highlight NONJA's strong community, high burned liquidity, and successful NFT collections, believing it to be a resilient and undervalued gem poised for substantial growth.

English version Introducing SWFTCoin (SWFTC) $SWFTC: Powering SWFT Blockchain and AI Services (SWFTGPT)  SwftCoin ($SWFTC) is the native utility token driving SWFT Blockchain's AI-powered ecosystem, SWFTGPT, and the first ever AI token featured on Coinbase. SWFTGPT is also the first domain-specific LLM for crypto.  SwftCoin key features include: 50% Reduced Transaction Fees: Lower costs on all transactions. AI Service Payments: Use $SWFTC to access SWFTGPT. Tools include expert market analysis,  predictions, and intelligent trading solutions.  Membership Benefits: Unlock premium features and AI agent services within SWFTGPT. AI-Powered Swaps: Enable precise, fast cross-chain transactions and analytics. SWFT Blockchain combines AI innovation with blockchain infrastructure, simplifying crypto trading while enhancing functionality through $SWFTC.   Chinese version $SWFTC：驱动 SWFT Blockchain 和 AI 服务（SWFTGPT） SwftCoin ($SWFTC) 是 SWFT Blockchain 的原生实用代币，为其 AI 驱动的生态系统 SWFTGPT 提供支持，同时也是 Coinbase 上首个 AI 代币。SWFTGPT 也是首个专注于加密领域的特定领域大型语言模型 (LLM)。 SwftCoin 的主要功能包括： 1、50% 交易费减免：降低所有交易成本。 2、AI 服务支付：使用 $SWFTC 访问 SWFTGPT 工具，包括专家市场分析、预测以及智能交易解决方案。 3、会员权益：解锁 SWFTGPT 的高级功能和 AI 代理服务。 4、AI 驱动的闪兑：实现精准快速的跨链交易和数据分析。 SWFT Blockchain 将 AI 创新与区块链基础设施结合，通过 $SWFTC 简化加密交易，并提升其功能性。

SwftCoin

SwftCoin (SWFTC) is trending with increased community engagement, driven by buzz surrounding potential new major exchange listings, notably Coinbase, and a significant surge in trading volume. The community is actively discussing its fully diluted supply, AI-integrated exchange, and cross-chain bridging technology, anticipating substantial "altseason" gains and its pivotal role in the evolving multi-chain ecosystem.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is trending due to recent announcements regarding the expansion of its anticoagulant drug pipeline through new acquisitions, including a 12-LOX inhibitor for heparin-induced thrombocytopenia (HIT), and strategic collaborations for its tecarfarin program. This has sparked a divided community, with many investors anticipating significant upside from its low float and regulatory designations, while a vocal group expresses strong skepticism, citing concerns over potential dilution and the company's financial stability. The ongoing conversation centers on whether these pipeline advancements will solidify CVKD's position as a multi-asset biotech.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is buzzing with renewed optimism following its partnership with Google Cloud for AI agent development, alongside growing real-world adoption exemplified by new enterprise deals. The community is actively discussing FET as an undervalued asset, anticipating substantial growth as the decentralized AI and machine economy narratives gain traction. Many investors view current price levels as a key accumulation opportunity, confident in its strategic positioning within the evolving AI landscape.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance (AERO) is a trending topic, driven by its recent listing on Robinhood and its pivotal role as the leading liquidity hub on the rapidly expanding Base network. The community is buzzing about its robust revenue generation, strategic tokenomics, and an anticipated merger with Velodrome that aims to establish a powerful cross-chain DeFi ecosystem. Despite broader market uncertainties, many view AERO as a fundamental player positioned for significant growth.

EHang Holdings Ltd. engages in the provision of aerial vehicle technology platform company. It also provides unmanned aerial vehicle (UAV) systems and solutions: air mobility (including human transportation and logistics), smart city management, and aerial media solutions. The firm operates through the following geographical segments: P.R.C., West Asia, East Asia, South America, Europe, and Other. The company was founded by Huazhi Hu and Yifang Derrick Xiong in December 2014 and is headquartered in Guangzhou, China.

EHang Holdings Ltd - ADR

EHang Holdings

EHang Holdings is trending amid a split investor sentiment following a significant reduction in its full-year revenue guidance and a subsequent analyst downgrade. While some investors express frustration over the stock's performance and management's consistency, others remain bullish, pointing to the company's continuous progress in autonomous eVTOL technology and upcoming commercial operational launches in regions like Thailand and Saudi Arabia.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech stocks remain a hot sector for retail traders on Stocktwits,&nbsp;which collectively boast over 3.45 million followers.&nbsp;In January, several biotech names saw explosive gains as investors bet on breakthrough treatments, key partnerships, and regulatory milestones.According to Stocktwits data, these five biotech stocks saw the highest surge in retail following this month.CARGO Therapeutics Inc. (CRGX) – 445% Jump In FollowersCARGO Therapeutics, a clinical-stage biotech company focused on cancer treatments, saw its stock collapse even as retail interest surged.&nbsp;In January, the FDA cleared its Investigational New Drug (IND) application for CRG-023, a novel tri-specific CAR T therapy designed to tackle relapse factors in B-cell malignancies.&nbsp;However, the company later announced it would discontinue a Phase II trial of its lead candidate, firi-cel, after an ad hoc safety analysis revealed an unfavorable benefit-risk profile.&nbsp;Wall Street analysts issued downgrades, and CARGO’s stock is on track to plunge more than 76% in January — its worst month since going public in November 2023.&nbsp;Short interest stands at 15.1%, according to Koyfin data.Sana Biotechnology Inc. (SANA) – 185% Jump In FollowersSana Biotechnology, which focuses on engineered cell therapies, captured investor attention with a potential&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sana-biotech-stock-triples-after-type-1-diabetes-trial-data/chGBWsVRZO">breakthrough</a> in type 1 diabetes.&nbsp;The company demonstrated earlier this month that its hypoimmune edits allowed islet cell transplant survival without immunosuppression.&nbsp;Analysts praised the findings, driving the stock up roughly 114% in January — its best month since its March 2021 market debut.&nbsp;Short interest is at 16.6%.Silexion Therapeutics Corp. (SLXN) – 92% Jump In FollowersSilexion, an oncology-focused biotech developing RNA interference therapies, gained momentum after releasing preclinical data on a second-generation siRNA candidate, SIL-204.&nbsp;The treatment&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/slxn-stock-hits-record-low-after-pricing-5m-offering/chGtwKoRng">showed</a> synergistic efficacy when combined with first-line chemotherapy for pancreatic cancer.&nbsp;Although the stock gained just 2% in January, it marked its best month since November.&nbsp;Short interest remains low at 2.4%.AEON Biopharma Inc. (AEON) – 81% Jump In FollowersAEON Biopharma is developing ABP-450, a botulinum toxin complex similar to Evolus’ Jeuveau, for medical indications such as chronic migraine.&nbsp;Retail traders appeared to buy the dip after AEON priced a $20 million public offering earlier this month, which initially sent shares tumbling.&nbsp;The stock is headed for a 77% drop in January, its worst month since going public via a SPAC merger in July 2023.&nbsp;Short interest is just 0.2%, according to Koyfin.Kairos Pharma (KAPA) – 78% Jump In FollowersKairos Pharma, a clinical-stage biopharmaceutical company, saw retail interest soar this month after breaking key resistance levels and securing crucial investments.&nbsp;The company is testing its lead candidate, ENV105 — which targets a protein linked to resistance in cancer treatments — in Phase 2 trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer.The stock gained momentum following CEO John Yu’s positive comments at an investor healthcare summit this month and the completion of a $3.5 million PIPE transaction.&nbsp;Kairos shares are set to decline 2.6% in January, marking their worst month since October.&nbsp;Short interest remains&nbsp;negligible at 0.1%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why

Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.

Equity

Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.


Three nano-cap healthcare stocks drew massive attention from retail investors on Stocktwits Tuesday, though not all for positive reasons.Trinity Biotech (<a href="https://stocktwits.com/symbol/TRIB">TRIB</a>)&nbsp;Shares of the medical diagnostic products maker saw a staggering 15,550% jump in retail message volume after the company released “compelling” results from a study on its next-generation continuous glucose monitoring system.&nbsp;The device, designed for real-time diabetes management, demonstrated superior signal quality, accuracy, and consistency in a trial involving 30 diabetic participants.&nbsp;The system features a reusable applicator and rechargeable wearable transmitter, reducing costs by eliminating disposable components.&nbsp;Trinity said it remains on track to seek regulatory approval in the EU by 2025 and the U.S. by 2026.&nbsp;Shares fell over 13% premarket Wednesday.Silexion Therapeutics (<a href="https://stocktwits.com/symbol/SLXN">SLXN</a>)&nbsp;The cancer-focused biotech firm’s ticker saw a 9,060% surge in retail message volume as its stock more than doubled Tuesday following promising preclinical data for its tumor drug candidate SIL-204.&nbsp;The company reported that the extended-release formulation of SIL-204 reduced tumor growth by more than 50% after 30 days, with around 50% of tumors showing complete necrosis in human pancreatic models.&nbsp;Additionally, an injectable version of the drug candidate showed tumor growth inhibition in metastatic pancreatic mouse models.&nbsp;The stock continued its rally, gaining over 70% premarket Wednesday.Sharps Technology (<a href="https://stocktwits.com/symbol/STSS">STSS</a>)&nbsp;The medical packaging firm experienced a 6,233% surge in retail message volume, but for the wrong reasons.&nbsp;Shares plunged nearly 70% to a record low on Tuesday after the company announced a $20 million public offering of 14,285,714 Common Units.&nbsp;Each unit consists of one share of common stock, one Series A warrant, and one Series B warrant, priced at $1.40 per unit, a 4.1% discount to Monday’s close.&nbsp;The company said the proceeds would be used for general corporate purposes and working capital.&nbsp;The stock continued to slide, down over 2% premarket Wednesday.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

TRIB, SLXN, STSS: Why Retail Chatter On 3 Nano-Cap Healthcare Stocks Exploded Over 6000%

“Compelling” results from a study, promising pre-clinical data and a public offering got Stocktwits investors buzzing on Tuesday.

Shares of Silexion Therapeutics lost&nbsp;more than a quarter of their market capitalization on Thursday morning, hitting a record intraday low after the company priced a $5 million public offering late Wednesday.The stock is also on track for its worst day since Dec. 26.The offering includes approximately 3.7 million ordinary shares and accompanying warrants for&nbsp;purchasing up to 3.7 million additional shares.&nbsp;Priced at $1.35 per share and warrant, the offering was below Wednesday’s closing price of $1.56.&nbsp;The warrants, which will expire five years from issuance, carry an exercise price of $1.35 and are exercisable immediately. The offering is expected to close on Friday.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SLXN_sentiment_and_message_volume_Jan_16_ebe16b64bc.png" alt="SLXN sentiment and message volume Jan 16.png" width="1318" height="324"><figcaption>SLXN sentiment and message volume Jan 16 as of 10 am ET | source: Stocktwits</figcaption></figure>Despite the steep decline in share price, retail sentiment for Silexion was ‘extremely bullish’ on Stocktwits, where message volume surged to a six-month high.&nbsp;Some users voiced plans to buy shares once the offering concludes, while others noted the company’s low float, available cash, and technical levels as reasons for cautious optimism.<stembedurl>https://stocktwits.com/Kevin_Gough/message/600264740</stembedurl><stembedurl>https://stocktwits.com/Patience__/message/600239429</stembedurl><stembedurl>https://stocktwits.com/StockProphercy/message/600293377</stembedurl>Fueling this sentiment further is Wednesday’s release of encouraging preclinical data for Silexion’s experimental pancreatic cancer treatment, SIL-204.&nbsp;According to the company, SIL-204 demonstrated strong synergistic effects when combined with common chemotherapeutic agents, including 5-fluorouracil, irinotecan, and gemcitabine, in human cell lines with KRAS G12D mutations, the most prevalent type of pancreatic cancer.Silexion said it plans to initiate toxicology studies for SIL-204 within the next few months, with phase 2/3 clinical trials scheduled for the first half of 2026.&nbsp;Financially, Silexion ended the third quarter of 2024 with cash and equivalents totaling $2 million and debt near $230,000, according to Koyfin.&nbsp;However, the stock has lost over 98% of its value in the past year, reflecting challenges that may&nbsp;affect its prospects.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Silexion Stock Hits Record Intraday Low After Pricing $5M Offering, But Retail Excitement Over Cancer Data Endures

Priced at $1.35 per share and warrant, the offering was below Wednesday’s closing price of $1.56.

The market’s resilience came under test on Wednesday as apprehensions ahead of earnings from artificial intelligence stalwart Nvidia Corp. (<a class="mention" data-mention="$NVDA" data-symbol-id="NVDA" href="https://stocktwits.com/symbol/NVDA" target="_blank">$NVDA</a>) generated some weakness early in the session.Nvidia stock was last seen trading down more than 1%, giving back some of the nearly 5% gain it made on Wednesday.As traders look ahead to the company’s market-moving&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ai-stalwart-nvidia-to-report-q3-2025-results-wednesday/cJ4UNCxRQC">earnings report,</a> due after the market close, here is a compilation of the most bullish stocks on Stocktwits:Forte Biosciences, In. (<a class="mention" data-mention="$FBRX" data-symbol-id="FBRX" href="https://stocktwits.com/symbol/FBRX" target="_blank">$FBRX</a>)&nbsp;Forte Biosciences shares were last seen rallying over 170% as the nano-cap autoimmune disorders-focused clinical-stage biopharma said its equity financing to support the continuing clinical advancement of its lead candidate FB102 was oversubscribed. “ As a result of the financing, Forte is well capitalized to continue advancing FB102 across autoimmune indications,” it added.Quantum-Si Inc. (<a class="mention" data-mention="$QSI" data-symbol-id="QSI" href="https://stocktwits.com/symbol/QSI" target="_blank">$QSI</a>):Shares of Quantum-Si, a medical-device company that develops a single-molecule detection platform to enable next-gen protein sequencing (NGPS), more than doubled on Wednesday on volumes that are notably above their 3-month average.The upside came after the company made a slew of announcements. Quantum-Si said Avantor, Inc. (<a class="mention" data-mention="$AVTR" data-symbol-id="AVTR" href="https://stocktwits.com/symbol/AVTR" target="_blank">$AVTR</a>) will distribute its NGPS portfolio, providing researchers across the U.S. and Canada access to the portfolio.In a separate release, Quantum-Si announced a collaboration with Nvidia to develop its next proteomics platform called Proteus and advance its core technologies of amino acid binders and amino peptidases using Nvidia AI and accelerated computing.&nbsp;Quantum-Si also announced an expanded partnership with SkyWater Technology, Inc. (<a class="mention" data-mention="$SKYT" data-symbol-id="SKYT" href="https://stocktwits.com/symbol/SKYT" target="_blank">$SKYT</a>) for developing Proetus and a separate deal with its contract manufacturing partner Planet Innovation for the same.&nbsp;Silexion Therapeutics Corp. (<a class="mention" data-mention="$SLXN" data-symbol-id="SLXN" href="https://stocktwits.com/symbol/SLXN" target="_blank">$SLXN</a>)Silexion, a clinical-stage biotech developing RNA interference therapies for certain types of cancers, disclosed in a filing on Tuesday that at the reconvened extraordinary general meeting, its shareholders approved the board recommendation for a reverse split of the shares in the ratio 1-for-9.&nbsp;The penny stock climbed 33% on Wednesday on above-average volume.Duos Technologies Group, Inc. (<a class="mention" data-mention="$DUOT" data-symbol-id="DUOT" href="https://stocktwits.com/symbol/DUOT" target="_blank">$DUOT</a>)Shares of Jacksonville, Florida-based Duos Tech, a software services provider, climbed over 17% after the company announced the signing of a $42 million worth of asset management agreement with Fortress Investment Group to deploy and operate a fleet of mobile gas turbines and balance-of-plant inventory that has a combined generation capacity of 850 megawatts.ZIM Integrated Shipping Services Ltd. (<a class="mention" data-mention="$ZIM" data-symbol-id="ZIM" href="https://stocktwits.com/symbol/ZIM" target="_blank">$ZIM</a>)Cargo shipping firm ZIM Integrated reported <a href="https://stocktwits.com/news-articles/markets/equity/zim-integrated-shipping-stock-rises-premarket-after-strong-q3-earnings/cJ46SQoRXc">upbeat third-quarter earnings</a> and raised its full-year guidance, sending its shares higher by over 7%. Retail hoped for large buyers increasing their exposure to the stock, sending it to the $31-$32 area by the close.<stembedurl>https://stocktwits.com/View2021/message/593365202</stembedurl>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-q3-2025-earnings-imminent/cJ46Z2LRXE">Nvidia Stock Slips Ahead Of Earnings: Gene Munster Explains Why Blackwell Chip Demand Commentary Is Important For Investors</a>

US Stocks dipped ahead of Nvidia earnings but a few sent retailers into a tizzy. 

5 Stocks Retail Investors Are Most Bullish On At Mid-Day

Retailers went overboard about a couple of biotech stocks and a MedTech name, among others on Wednesday.

Silexion Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery and development of treatments for KRAS-driven cancers. The company was founded on November 30, 2008 and is headquartered in in Modiin, Israel.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$1.12	--	--	N/A
Q3 '25	-$3.40	-$2.88	15.29%	BEAT
Q2 '25	-$3.15	-$4.32	-37.14%	MISSED
Q1 '25	-$0.22	-$3.90	-1672.73%	MISSED
Q4 '24	-$0.98	--	--	N/A

SLXN
Silexion Therapeutics Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest SLXN News

SLXNSilexion Therapeutics Ltd